Insurance doesn't cover this. Three things might defray it.
When patients ask "does insurance cover this," they are usually asking three different questions at once: will my insurer reimburse me, can I pay with pre-tax dollars, and is any of this deductible at tax time. The answers are different. Insurance reimbursement is essentially never. Pre-tax payment via HSA or FSA is sometimes, and the conditions are knowable in advance. Itemized deduction under IRS §213 is patient-specific and depends on facts a CPA needs to see. Below: the matrix, the rules, the documentation we provide, and a clear line on what we will not pretend to know.
One caveat up front, which we repeat throughout this page and mean every time: we are not a tax advisor. Nothing here is tax advice. The rules below cite the actual IRS sections and publications so that you and your CPA can read them directly. Our job is to tell you what is structurally true about the program and to hand you documentation precise enough to make your CPA's job possible.
~0%. Plan on zero.
Mesenchymal stem cell therapy for our indications is not FDA-approved and is treated as investigational. Every major U.S. insurer has explicit non-coverage language. Out-of-network claims are denied.
Sometimes. Documented.
Some plan administrators reimburse with a Letter of Medical Necessity. We can write one on request; many patients prefer their own U.S. physician's letter, which often reads as stronger to an administrator. Either way, many plans won't reimburse investigational treatment at all. Verify with your administrator before counting on it.
Possibly. If you itemize.
Medical expenses over 7.5% of AGI may be deductible if treatment qualifies under §213(d). Foreign medical care is eligible in principle; the documentation has to be tight. CPA territory.
The matrix, read horizontally.
Each row below is a line item from a typical Celva program. Each column is one of the four mechanisms a U.S. patient might use to defray it. The marks are honest about which combinations actually work and which are wishful thinking, the green checks are where the system genuinely lets the dollar flow; the yellow tildes are where it's case-by-case; the red dashes are where the answer is reliably no.
Four mechanisms, eight line items.
Two readings of the matrix. The narrow reading: the therapy itself: the infusion, the cells, the hospital fees on the day of treatment, is the line item that gets denied across the board for insurance and turns into a coin flip for HSA/FSA. The broader reading: the surrounding clinical workup is reimbursable through normal channels. Your U.S. PCP visits, your own pre-treatment imaging, the labs, the follow-up care, that part of the journey runs through your existing benefits the same as any other condition you're managing. The Mexico day is the exception, not the rule.
The same program, four ways the IRS will see it.
To make the matrix concrete, here is how a single-infusion program breaks out by where each dollar actually lands. The proportions are typical and the tax treatment of each bucket is fixed. The takeaway is that the "deductible portion" is larger than most patients assume, and the "HSA-eligible portion" depends more on your plan administrator than on us.
How the same dollar gets categorized for tax purposes.
Cells, lab manufacturing, hospital day-of fees, anesthesia. No insurance applies. HSA/FSA only if your plan administrator accepts a Letter of Medical Necessity, either from your U.S. physician or from us on request, for investigational treatment. Many don't.
Therapy + hospital + physician consults + diagnostic workup + qualifying transportation. Deductible if you itemize and the total exceeds 7.5% of AGI. Not all programs cross that threshold alone, but bundled with other medical, often.
U.S. consults, your own pre-treatment imaging, U.S. labs. The reliably HSA/FSA-eligible portion. Submit standard receipts. No LMN required for these line items.
Meals, non-qualifying lodging overage, sightseeing, companion expenses beyond the §213 caps. No mechanism applies. Plan as out-of-pocket personal expense.
The four buckets do not add to 100% because they overlap, a single line item can sit in more than one (e.g., a pre-treatment U.S. scan is both HSA-eligible and §213-deductible; same dollar, two mechanisms, you pick the better one). The right way to read the figure is as four separate views of the same payment, not as a stack. A patient who itemizes and has a flexible HSA will recover meaningfully more than a patient who does neither. This is why a clean treatment invoice matters even when the path is uncertain; whichever mechanism you pursue, the receipt is the document that ties the cost to the care.
Five questions, in order.
The IRS rules for medical expense deductibility live in 26 U.S.C. §213 and IRS Publication 502. The relevant questions, applied to cell therapy abroad, are straightforward but specific. Walk through them in order. If you get to the end with green pills, the treatment likely qualifies under §213(d); if a pill is yellow, the answer depends on your specific facts and your CPA's reading; if any pill is red, that's the stopping point and the rest of the tree doesn't matter.
How the IRS reads cell therapy abroad.
Medical care is defined as "amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease, or for the purpose of affecting any structure or function of the body." Cell therapy administered for a diagnosed condition: autoimmune, neurodegenerative, orthopedic, fits that definition on its face. Wellness or "anti-aging" infusions without a diagnosis do not.
No. §213 does not require FDA approval. The IRS test is whether the expense is for medical care as defined above. Pub 502 explicitly lists "treatments at a medical center" and does not require those treatments to be FDA-approved. The agency has historically allowed deductions for experimental and foreign treatments where there is documented medical necessity.
No, in principle. The IRS explicitly contemplates foreign medical care in Pub 502 and provides specific rules for related travel. The treatment must be legal in the country where performed (it is) and must qualify as medical care under Q1 (it does). What changes abroad is the travel-expense treatment, not the medical-expense treatment itself.
For travel costs to qualify, the trip must be primarily for medical care, not a vacation that happens to include a doctor's visit. A trip to Tijuana for a scheduled infusion and follow-up: five-to-seven days, structured around clinical appointments, meets this. Extending the trip for tourism doesn't disqualify the medical portion, but only the medical-day expenses count.
Only the amount above 7.5% of adjusted gross income is deductible. For a household with $150,000 AGI, the threshold is $11,250. A cell-therapy program of this scale plus other medical expenses in the same year typically crosses it. For higher AGIs, the program alone may not. You also have to itemize (Schedule A) rather than take the standard deduction; whether that's better is your CPA's call.
The treatment itself, the hospital fees, the qualifying physician consults, and the qualifying transportation are deductible medical expenses under §213(d). The mechanics: Schedule A, Form 1040, supporting documentation, are your CPA's lane. Our job is to make sure the receipt is precise enough that the CPA can do theirs.
Three observations about how the levers interact. The 7.5% floor matters more than the marginal rate. At $300k AGI the floor is $22,500 before any deduction begins, so a higher-AGI patient with no other medical expenses in the year may net almost nothing. Bundling matters. A patient who schedules the program in a year with other significant medical events (a surgery, a baby, orthodontia) crosses the floor more decisively. The standard-deduction comparison matters. The 2024 standard deduction for joint filers is $29,200; if your total Schedule A (medical + SALT + mortgage interest + charitable) doesn't beat that, itemizing the medical produces no benefit at all. These three levers are why "is it deductible" is the wrong question. the right one is "is it deductible this year, in your specific facts". and that question lives at your CPA's desk, not ours.
What §213 says about getting to Mexico.
Travel and lodging for medical care have their own rules, narrower than the medical expenses themselves. The headline number to remember is $50 per night per person that is the IRS cap on deductible lodging for medical travel, applied separately to the patient and to one accompanying person. Meals are not deductible at all. Transportation to the medical care is deductible at cost. Below is the line-by-line.
What goes on Schedule A, and what doesn't.
How the rules stack on a real trip. Round-trip airfare for the patient is deductible at actual cost. A spouse's airfare is deductible too when an LMN supports companion necessity post-infusion. Lodging is where the cap bites: a five-night stay at any nightly rate still deducts at only $50 per night for the patient, plus $50 per night for a medically necessary companion sharing the room. Ground transport across the border and to the hospital is deductible at actual cost. Meals are not deductible at all. The lesson is the shape, not a total: flights and ground transport flow through at cost, lodging is throttled to the statutory cap, and meals fall out entirely.
The invoice we hand you, and what you assemble yourself.
The most important thing we hand you on the payment side is a clean treatment invoice: patient name, treatment date, Hospital Angeles, treatment description (e.g., "MSC IV infusion · Hospital Angeles Tijuana"), the line items, and the total paid. That receipt is what your HSA administrator or CPA needs to see we performed the procedure. The clinical narrative around it, the diagnosis codes, the prior-treatments-tried list, lives with your U.S. physician, who knows you and has your records. The Letter of Medical Necessity is its own decision: we'll write one on request as part of the concierge service. Many patients find a letter from their own U.S. physician carries more weight with an administrator, since that physician has the longitudinal record. Both are real options. Below: the flow that actually works, what we send by default, and what you assemble yourself.
What actually happens after the procedure.
The invoice covers the line items (IV infusion, intra-articular injection if applicable) with patient name, date, hospital, and treatment description. Scan it before leaving Tijuana. Most administrators accept PDFs.
A Letter of Medical Necessity. From your U.S. physician (PCP, specialist, or referring physician) who knows your case, or from us on request. Many patients find their U.S. physician's letter reads stronger to an administrator. Diagnosis documentation comes from your existing U.S. medical records. Together with the treatment invoice, this is the package that goes to your HSA administrator or to your CPA for §213.
Through the administrator's portal or app. Upload the LMN, the diagnosis documentation, and the treatment invoice. The LMN is the document that does the work. A clinical letter saying this patient, this diagnosis, this rationale, here is why this treatment was medically necessary is what an administrator reads. Without it, the invoice alone usually isn't enough.
A human reviewer (sometimes a clinician on contract) reads the LMN and the invoice. The decision turns on plan language and reviewer interpretation more than on federal law. Outcomes split:
A single appeal letter, citing IRS §213(d), Pub 502, your physician's LMN, and any plan language that supports medical necessity, reverses the decision in about a third of cases. Past the first appeal, the marginal effort isn't worth it; refile the same expenses as §213 itemized deductions on Schedule A at tax time. The same documentation supports both filings.
Whether reimbursed by HSA, deducted under §213, or paid out-of-pocket, keep the full package: treatment invoice, LMN, diagnosis documentation, appeal correspondence. The IRS audit window for substantial understatement is six years; cell-therapy line items are exactly the kind of unusual deduction that draws a second look.
The same LMN, different administrators, different outcomes.
The ranges above are industry-reported approximations, not Celva-specific data. The pattern: independent HSA custodians are the friendliest to investigational treatment with a strong LMN; insurance-bundled and employer-FSA administrators are the toughest. If your plan is on the strict end of this distribution, the right call is often to skip the HSA submission entirely and route the same expenses through §213 at tax time, the documentation overlaps almost completely and the floor is more predictable than the administrator's discretion. Either way, the receipt and the LMN are the two documents that do the work.
What we send. What we'll add on request. What you assemble.
- Patient name and treatment date. Tied to the date of the procedure.
- Hospital identifier. Hospital Angeles Tijuana, named on the invoice.
- Treatment description. Plain English (e.g., "MSC IV infusion" or "MSC IV infusion + intra-articular injection, right knee").
- Line items. IV infusion cost. Intra-articular injection cost, if applicable. Total paid.
- Letter of Medical Necessity. Drafted by your Celva attending, formatted to HSA-administrator expectations, naming the diagnosis, the medical necessity, and the absence of comparable U.S.-approved alternatives. We'll write one when requested. Note: many patients find a letter from their own U.S. physician reads stronger, since that physician has the longitudinal record.
- Diagnosis documentation. From your existing U.S. medical records. ICD-10 codes, prior treatments tried and failed, clinical history. Your PCP or specialist already has this.
- A CPA who's comfortable with §213 medical deductions. Your own. The §213 deduction lives on your Schedule A and turns on facts that only your full return can show.
The asymmetry is intentional. We give you the receipt of services. We'll write an LMN when you ask. Everything else, the diagnosis codes, the clinical narrative, the tax-return judgment, lives where it should: with the U.S. physicians who know you and have your records, and with the CPA who has your full return.
- File insurance claims on your behalf. Out-of-network claims for investigational stem cell therapy are denied at the door. We won't pretend to chase them and add a "billing fee" for the courtesy.
- Tell you whether it's deductible. That is your CPA's call against your full tax picture. We can tell you what §213 says; we can't tell you what your return will look like.
- Write an LMN our medical team doesn't believe. The LMN is a clinical document signed by a licensed physician. If your case doesn't medically support it, the attending will not sign it, and you should not want them to.
- Backdate or restructure invoices to fit a tax year, a plan year, or an HSA balance window. The invoice date matches the procedure date.
- Bundle non-medical expenses as medical. A program that disguises non-medical spending to inflate a deduction is fraud. We itemize honestly even when itemizing honestly produces a smaller deduction.
- Claim insurance covers what it doesn't. If a sales call ever tells you "most insurance covers this," that is structurally false. It is false for everyone in this category, including us.
Before you assume anything is recoverable.
- Call your HSA/FSA administrator and ask explicitly: "Does our plan reimburse investigational mesenchymal stem cell therapy with a Letter of Medical Necessity?" Get the answer in writing. Some say yes; some say no.
- Ask your CPA about itemizing this year. If your medical expenses won't cross 7.5% of AGI, the deduction is zero regardless of how well-documented the program is.
- Confirm your companion's eligibility before booking. Without an LMN supporting medical necessity, the second airfare and the second lodging are personal expenses.
- Don't extend the trip for tourism if you intend to deduct travel. Days beyond the medical schedule are personal and produce documentation problems if itemized.
- Save the itemized receipt for seven years. The IRS audit window for substantial understatement is six years; one year of buffer is cheap insurance.
Insurance, no. HSA/FSA, sometimes. §213, often, if you itemize.
Commercial insurance does not cover MSC therapy for our indications and will not, plan on zero. HSA and FSA reimbursement depends on your plan administrator's tolerance for investigational treatment plus a Letter of Medical Necessity, either from your U.S. physician or from us on request; some plans accept, some don't. The IRS §213 itemized deduction is the most reliable lever for U.S. patients who itemize and whose medical expenses cross 7.5% of AGI: the treatment, hospital fees, qualifying consults, and qualifying transportation all count, with travel capped at $50/night/person for lodging and meals excluded entirely. We hand you the treatment invoice and the LMN when you ask; your CPA does the math. We will not file insurance, draft documentation we shouldn't be writing, or claim coverage that doesn't exist.